Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Giralt
    Giralt
  2. Hassoun
    Hassoun
  3. Landau
    Landau
  4. Arcila
    Arcila
  5. Dogan
    Dogan
  6. Hultcrantz
    Hultcrantz
  7. Lesokhin
    Lesokhin
  8. Park
    Park
  9. Roshal
    Roshal
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (16)
  2. Department of Medicine (16)
  3. Hematologic Malignancies, Division of (16)
  4. Myeloma (16)
  5. Hematologic Malignancies Research (12)
  6. Bone Marrow Transplant (4)
  7. Sloan Kettering Institute Postdocs (4)
  8. Survivorship Research (4)
  9. Population Sciences Research Program (3)
  10. Adult Leukemia (2)
Search Within
  1. "Myeloma"
Formats
  1. Journal Article (13)
  2. Meeting Abstract (3)
Groups
  1. Center for Hematologic Malignancies (16)
  2. Department of Medicine (16)
  3. Hematologic Malignancies, Division of (16)
  4. Myeloma (16)
  5. Hematologic Malignancies Research (12)
  6. Bone Marrow Transplant (4)

More Groups

People
  1. Carl Landgren (9)
  2. Ahmet Dogan (4)
  3. Caleb Ho (3)
  4. Even Rustad (3)
  5. Hani Hassoun (3)
  6. Heather Landau (3)

More People

Years
  1. 2021 (3)
  2. 2020 (5)
  3. 2019 (2)
  4. 2018 (2)
  5. 2017 (2)
  6. 2016 (1)

More Years

Publications
  1. Journal of Molecular Diagnostics (4)
  2. Lancet Oncology (4)
  3. The Lancet Haematology (3)
  4. Lancet (2)
  5. Value in Health (2)
  6. Journal of the American College of Cardiology (1)

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study
    Journal Article

    Berdeja, J. G.; Madduri, D.; Usmani, S. Z.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Stewart, A. K.; Hari, P.; Htut, M.; Lesokhin, A.; more...
    Lancet (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: Feasibility, challenges, and direct comparison with high-sensitivity flow cytometry
    Journal Article

    Ho, C.; Syed, M.; Roshal, M.; Petrova-Drus, K.; Moung, C.; Yao, J.; Quesada, A. E.; Benhamida, J.; Vanderbilt, C.; Liu, Y.; more...
    Journal of Molecular Diagnostics (2021)

    Fulltext@MSK | Save
  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study
    Journal Article

    Dimopoulos, M.; Quach, H.; Mateos, M. V.; Landgren, O.; Leleu, X.; Siegel, D.; Weisel, K.; Yang, H.; Klippel, Z.; Zahlten-Kumeli, A.; more...
    Lancet (2020)

    Fulltext@MSK | Save
  • Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma
    Journal Article

    Martins, C. O.; Huet, S.; Yi, S. S.; Ritorto, M. S.; Landgren, O.; Dogan, A.; Chapman, J. R.
    Journal of Molecular Diagnostics (2020)

    Fulltext@MSK | Save
  • Incremental value of GLS for classification of prognosis in patients with advanced light chain (AL) amyloidosis
    Meeting Abstract

    Nahhas, O.; Lee Chuy, K.; Yang, J. C.; Landau, H.; Drill, H.; Hassoun, H.; Chen, C. L.; Yu, A. F.; Steingart, R. M.; Liu, J. E.
    Journal of the American College of Cardiology (2020)

    Fulltext@MSK | Save
  • Critical appraisal of published indirect comparisons and network meta-analyses of competing interventions for multiple myeloma
    Journal Article

    Cope, S.; Toor, K.; Popoff, E.; Fonseca, R.; Landgren, O.; Mateos, M. V.; Weisel, K.; Jansen, J. P.
    Value in Health (2020)

    Fulltext@MSK | Save
  • Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study
    Journal Article

    Lonial, S.; Lee, H. C.; Badros, A.; Trudel, S.; Nooka, A. K.; Chari, A.; Abdallah, A. O.; Callander, N.; Lendvai, N.; Sborov, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Establishment of immunoglobulin heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of B-cell and plasma cell neoplasms
    Journal Article

    Arcila, M. E.; Yu, W.; Syed, M.; Kim, H.; Maciag, L.; Yao, J.; Ho, C.; Petrova, K.; Moung, C.; Salazar, P.; more...
    Journal of Molecular Diagnostics (2019)

    Fulltext@MSK | Save